MELA Sciences Announces First Quarter 2013 Financial Results
IRVINGTON, N.Y., April 30, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind^®, today announced financial results for the first
quarter ended March 31, 2013.
First Quarter 2013 Performance Highlights:
*Ended the first twelve months of the MelaFind commercial launch with
significant national distribution by having placements in 28 states in the
US and 21 cities in Germany.
*63% of US population within 75 miles of a MelaFind practice;
*Launched national ongoing PR campaign.
*Began concentrated effort on system usage, the second phase of our
two-phase commercial launch while continuing our phase one efforts to
enhance a firm and growing customer base.
*Ended the first quarter with signed user agreements for 138 MelaFind
systems in the US and Germany;
*Ended the first quarter with an installed base of 126 MelaFind systems
in the US and Germany and continue to work with dermatology customers to
successfully incorporate MelaFind into their practices;
*In discussions with over 140 additional dermatologist practices that
either have a user agreement currently under evaluation, or have been
classified as "highly interested" by the Company.
*Successful dermatology meetings in the US and Germany:
*American Academy of Dermatology (AAD) meeting in Miami, March 1st – 4th.
• MelaFind data were presented at ten podium presentations;
• Experienced strong booth traffic with over 650 dermatologists
engaged to learn more about MelaFind;
350 of which received in-depth demonstrations.
*Fachtagung: Dermatologische Praxis 2013 meeting, Frankenthal, Germany
• 76 in-depth demonstrations;
• MelaFind workshop with 110 attendees.
*Introduced additional pricing models to increase patient access and
simplicity for practices.
*Per session model; per lesion model, and monthly use options.
*Increased public relations initiatives to promote patient awareness and
*MelaFind appearance on The View as well as local new stations by
dermatologists in the US and Germany;
*Expanded distribution of in-office literature, website content, and
posters for dermatologists to better educate patients about MelaFind.
"We have now completed our first year on the market with MelaFind, and we are
pleased to report that we have established a significant nation-wide customer
base in the US and Germany, enabling us to move forward confidently with our
commercialization plans. We have now begun phase two of our launch – with
increased focus on patient awareness and engagement, as well as system usage,
and we believe that our efforts are starting to yield results– usage
represented 36% of our recognized revenue in the first quarter, up from 25% in
the fourth quarter of 2012," said Dr. Joseph V. Gulfo, President and CEO of
MELA Sciences."We look forward to continuing phase two of our launch as we
build upon a robust and growing base of customers and drive our business."
MelaFind is the Company's breakthrough non-invasive and objective automated
point of care system for use when a dermatologist chooses to obtain additional
information for a decision to biopsy clinically atypical pigmented skin
lesions with one or more clinical or historical characteristics of melanoma.
First Quarter 2013 Financial Results
Revenues for the three months ended March 31, 2013 were $144,100 compared to
$11,250 reported for the same period in 2012. Deferred revenues reported as of
March 31, 2013 were $392,250 versus deferred revenue of $17,250 reported as of
March 31, 2012. Revenues were based on the installation of 31 MelaFind systems
and do not account for 12 additional user agreements that were signed in the
first quarter of 2013 that are pending installation, scheduling, and training
of staff.Deferred revenues reflect the timed recognition of the installation
fee revenue over the term of the user agreement which is generally two years.
The Company's net loss for the three months ended March 31, 2013 was $6.5
million, or $0.17 per diluted share, compared to a net loss of $5.8 million,
or $0.19 per diluted share, for the same period in 2012. The increase in the
net loss was primarily attributable to Selling, General and Administrative
expenses related to the expansion of the Company's sales force and the
Company's incremental marketing costs as well as the increase in direct costs
associated with the placement of MelaFind systems in dermatologists' offices.
As of March 31, 2013, the Company's cash and cash equivalents were $21.6
MELA Sciences will host a conference call today at 4:30 PM EDT to discuss
first quarter 2013 quarterly results. To participate in the call, dial
1-877-303-9205 approximately 10 minutes before the conference call is
scheduled to begin. To listen via live webcast, please go to the investor
relations section of the MELA Sciences website at http://www.melasciences.com
approximately 10 minutes prior to the teleconference start time. If you are
unable to participate during the live conference call and webcast, the
conference call audio cast will be archived and available for replay for
approximately 90 days.
About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind^®, and its further design and development.
MelaFind is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind has received CE Mark approval and is approved for use in
the European Union.
For more information on MELA Sciences, visit www.melasciences.com.
This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the US Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind^® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at www.sec.gov and
MELA SCIENCES, INC.
CONDENSED BALANCE SHEETS
March 31, December 31,
Cash and cash equivalents $21,647,046 $7,861,524
Accounts receivable, net 169,403 179,956
Inventory 436,960 675,602
Prepaid expenses and other current assets 876,451 965,624
Total Current Assets 23,129,860 9,682,706
Property and equipment, net 8,495,801 7,349,531
Patents and trademarks, net 45,602 47,308
Deferred financing costs 79,877 106,141
Other assets 84,127 84,127
Total Assets $31,835,267 $17,269,813
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable (includes related parties of
$59,750 and $59,689 as of March 31, 2013 and $1,085,037 $1,850,102
December 31, 2012, respectively)
Accrued expenses 887,314 956,541
Deferred placement revenue 230,779 171,726
Other current liabilities 60,596 40,811
Total Current Liabilities 2,263,726 3,019,180
Long Term Liabilities:
Deferred placement revenue 161,471 131,651
Loan payable 5,286,037 --
Warrant liability 547,150 --
Long-term interest payable 7,417 --
Deferred rent 137,859 143,772
Total Long Term Liabilities 6,139,934 275,423
Total Liabilities $8,403,660 $3,294,603
Preferred stock — $.10 par value; authorized
10,000,000 shares; issued and outstanding: none
Common stock — $.001 par value; authorized
45,000,000 shares; issued and outstanding 43,037 32,205
43,037,144 shares at March 31, 2013 and 32,204,720
at December 31, 2012
Additional paid-in capital 172,100,055 156,142,873
Accumulated deficit (148,711,485) (142,199,868)
Stockholders' Equity 23,431,607 13,975,210
Total Liabilities and Stockholders' Equity $31,835,267 $17,269,813
* Derived from the audited balance sheet as of December 31, 2012
MELA SCIENCES, INC.
CONDENSED STATEMENTS OF OPERATIONS
Three months ended March 31,
Revenue $144,100 $11,250
Cost of revenue 1,080,263 130,410
Research and development 1,262,001 2,434,758
General and administrative 4,287,228 3,217,491
Operating loss (6,485,392) (5,771,409)
Interest income (2,105) (13,384)
Interest expense 48,763 --
Change in fair value of warranty liability (15,433) --
Other income, net (5,000) (5,000)
Net loss $(6,511,617) $(5,753,025)
Basic and diluted net loss per common share $(0.17) $(0.19)
Basic and diluted weighted average number of 39,233,943 30,313,905
common shares outstanding
MELA SCIENCES, INC.
CONDENSED STATEMENTS OF CASH FLOWS
Three Months Ended March 31,
Cash flows from operating activities:
Net loss $(6,511,617) $(5,753,025)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 496,733 148,044
Allowance for uncollectible accounts 40,000 --
Non-cash interest expense 14,101 --
Change in fair value of warrant liability (15,433) --
Write-off of unamortized financing costs 41,166 --
Non-cash compensation 268,381 347,618
Changes in operating assets and liabilities:
Increase in accounts receivable (29,447) (12,078)
Decrease (increase) in inventory 238,642 (310,090)
Decrease in prepaid expenses and other current 89,173 155,071
(Decrease) increase in accounts payable and (834,292) 75,391
(Decrease) increase in deferred rent (5,913) 1,389
Increase in deferred placement revenue 88,873 17,250
Increase in long-term interest payable 7,417
Increase in other current liabilities 19,785 13,887
Net cash used in operating activities (6,092,431) (5,316,543)
Cash flows from investing activities:
Purchases of property and equipment (1,641,297) (408,079)
Net cash used in investing activities (1,641,297) (408,079)
Cash flows from financing activities:
Proceeds from borrowings and issuance of warrant 6,000,000 --
Expenses related to borrowing and issuance of (245,358)
Proceeds from exercise of stock options 18,059 33,310
Net proceeds from public offerings 15,746,549 (4,293)
Net cash provided by financing activities 21,519,250 29,017
Net increase (decrease) in cash and cash 13,785,522 (5,695,605)
Cash and cash equivalents at beginning of period 7,861,524 27,996,871
Cash and cash equivalents at end of period $21,647,046 $22,301,266
Supplemental disclosure of cash flow information:
Non-cash investing activity:
Amortization of deferred financing costs $41,166 $--
Reclassification of MelaFind^® components from $-- $522,014
otherassets to property and equipment
CONTACT: For Investors
Press spacebar to pause and continue. Press esc to stop.